The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Open accessAbstract
Although in vitro models have been a cornerstone of anti-cancer drug development, their direct applicability to clinical cancer research has been uncertain. Using a state-of-the-art Taqman-based quantitative RT-PCR assay, we investigated the multidrug resistance (MDR) transcriptome of six cancer types, in established cancer cell lines (grown in monolayer, 3D scaffold, or in xenograft) and clinical samples, either containing >75% tumor cells or microdissected. The MDR transcriptome was determined a priori based on an extensive curation of the literature published during the last three decades, which led to the enumeration of 380 genes. No correlation was found between clinical samples and established cancer cell lines. As expected, we found up-regulation of genes that would facilitate survival across all cultured cancer cell lines evaluated. More troubling, however, were data showing that all of the cell lines, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model. Although cultured cells can be used to study many aspects of cancer biology and response of cells to drugs, this study emphasizes the necessity for new in vitro cancer models and the use of primary tumor models in which gene expression can be manipulated and small molecules tested in a setting that more closely mimics the in vivo cancer microenvironment so as to avoid radical changes in gene expression profiles brought on by extended periods of cell culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Established cell cultures have been the predominant research models of osteosarcoma for decades, but the culture-related alterations that cell lines acquire over tens and sometimes hundreds of passages 220,221 led to the development of systems for propagating osteosarcoma tumours 220,221 by creating libraries of primary tumour cell cultures and patient-derived xenografts (PDXs).”
From Osteosarcoma (2022) · cites this paper as [220]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, it has been shown that established cell lines do not capture disease heterogeneity across patients and hence are lacking in clinical relevance (Gillet et al., 2011; Yee et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Gillet et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our results confirm the low translational relevance of established cancer cell lines for the identification of clinical anti-cancer drug resistance [38].”
From Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“Among those genes, ATP-binding cassette (ABC) transporters, a superfamily of 48 highly homologous members classified in seven subfamilies, have an important role in the pleiotropic mechanisms mediating MDR by exporting chemotherapeutic agents from the cell (14, 15).”
BackgroundSelf-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Cited by
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
“Key methodologic aspects of selected PDX collections Reference Tumor type Available models Origin Procurement Processing Mice strain Implantation site Engraftment rate (28) CRC 130 Metastasis Surgery Fresh tumor pieces in Matrigel NOD/SCID s.c. 87% (29) CRC 54 Primary (35) Metastasis (19) Surgery Fresh tumor pieces Nu…”
BackgroundInfluentialEvaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
“Top right panels: neighbourhoods (1) of the top cell lines in our analysis, (2) of cell line IGROV1, and (3) of cell line A2780.”
BackgroundShen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955
“These inhibitors may have potential for future clinical application.”
BackgroundSelf-citationBeird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
The Clinical Relevance of Cancer Cell Lines
Gillet, J.-P., Varma, S., & Gottesman, M. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt007 · Cited by 599
“These mechanisms can act individually or synergistically, leading to MDR, in which cells become resistant to a variety of structurally and mechanistically unrelated drugs (28).”
BackgroundMethodResultInfluentialThe role of tumour-stromal interactions in modifying drug response: challenges and opportunities
McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3870 · Cited by 474
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
“Scie cause many preclinical models poorly reflect human disease, including cell lines (58).”
BackgroundPoynton, F. E., Bright, S. A., Blasco, S., Williams, D. C., Kelly, J. M., & Gunnlaugsson, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00680b · Cited by 421
Ruggeri, B. A., Camp, F., & Miknyoczki, S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.020 · Cited by 365
“Several studies have demonstrated that although critical genetic ‘‘driver’’ mutations [6] are often retained in tumor cell lines (as discussed further below), the loss of genetic fidelity results in tumor cells lines that more closely resemble each other regardless of tissue origin than the primary tumor from which th…”
BackgroundInfluentialYokoi, A., Yoshioka, Y., Yamamoto, Y., Ishikawa, M., Ikeda, S.-I., Kato, T., Kiyono, T., Takeshita, F., Kajiyama, H., Kikkawa, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms14470 · Cited by 334
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
“More troubling were data showing that all of the cancer cell lines, grown either in vitro or in vivo, bore more resemblance to each other, regardless of the tissue of origin, than to clinical samples from the same tissue of origin (58).”
BackgroundPreclinical mouse solid tumour models: status quo, challenges and perspectives
Gengenbacher, N., Singhal, M., & Augustin, H. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.92 · Cited by 332
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295
“…the cell lines that do exist, adaptation to in vitro culture and passaging for hundreds or even thousands of generations exerts substantial selective pressure that is not reverted by subcutaneous or even orthotopic xenografting (Daniel et al., 2009; Gillet et al., 2011; Hausser and Brenner, 2005).”
Patient-derived xenograft models of breast cancer and their predictive power
Whittle, J. R., Lewis, M. T., Lindeman, G. J., & Visvader, J. E. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0523-1 · Cited by 282
“Whilst they serve as useful tools, there are significant limitations, because continual passage of these cell lines is accompanied by extensive clonal selection and consequent loss of heterogeneity [19,20].”
BackgroundCurrent Applications of Nanoemulsions in Cancer Therapeutics
Sánchez-López, E., Guerra, M., Dias-Ferreira, J., Lopez-Machado, A., Ettcheto, M., Cano, A., Espina, M., Camins, A., Garcia, M. L., & Souto, E. B. (2019) · Nanomaterials · doi:10.3390/nano9060821 · Cited by 276
“Combination of DHA with paclitaxel resulted in a weak decrease in P-gp and ABC transporters [99].”
BackgroundPatient-derived xenograft (PDX) models in basic and translational breast cancer research
Dobrolecki, L. E., Airhart, S. D., Alferez, D. G., Aparicio, S., Behbod, F., Bentires-Alj, M., Brisken, C., Bult, C. J., Cai, S., Clarke, R. B., et al. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9653-x · Cited by 267
“Long-term culture has, in several cases, been associated with extensive clonal selection and loss of heterogeneity [94, 96].”
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
Saraf, A. J., Fenger, J. M., & Roberts, R. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00004 · Cited by 237
“Cell culture imposes widespread genetic changes and loss of phenotypic heterogeneity that diverge from the characteristics of the original tumor (63).”
BackgroundThree-Dimensional Cell Cultures: The Bridge between In Vitro and In Vivo Models
Urzì, O., Gasparro, R., Costanzo, E., De Luca, A., Giavaresi, G., Fontana, S., & Alessandro, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512046 · Cited by 224
“showed that the traditional 2D culture condition selects cells with rapid proliferation, growth, and better survival rate, causing the upregulation of many genes involved in cell cycle regulation and primary metabolic processes when compared with primary tumors [232], thus leading the tumoral cells to become progressi…”
BackgroundBorst, P. (2012) · Open Biology · doi:10.1098/rsob.120066 · Cited by 212
“Often there is doubt whether results obtained in established cell lines can be extrapolated to the behaviour of these cells when they were still in a tumour [84].”
Sanmamed, M. F., Chester, C., Melero, I., & Kohrt, H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw041 · Cited by 207
“However, the results obtained with these surrogate xenograft model systems have inadequately predicted human clinical outcomes, particularly in the case of targeted therapeutics [4, 27].”
BackgroundSzakács, G., Hall, M. D., Gottesman, M. M., Boumendjel, A., Kachadourian, R., Day, B. J., Baubichon-Cortay, H., & Di Pietro, A. (2014) · Chemical Reviews · doi:10.1021/cr4006236 · Cited by 203
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
Tseng, H.-C., Xiong, W., Badeti, S., Yang, Y., Ma, M., Liu, T., Ramos, C. A., Dotti, G., Fritzky, L., Jiang, J.-G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18444-2 · Cited by 196
Technologies for deriving primary tumor cells for use in personalized cancer therapy
Mitra, A., Mishra, L., & Li, S. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.03.006 · Cited by 193
“However, accumulation of genetic aberrations of cancer cell lines that occurs with increasing passage numbers has limited their clinical correlation [3, 4].”
BackgroundTorsvik, A., Stieber, D., Enger, P. Ø., Golebiewska, A., Molven, A., Svendsen, A., Westermark, B., Niclou, S. P., Olsen, T. K., Chekenya Enger, M., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.219 · Cited by 179
“Furthermore, in a comparative study to investigate the multidrug resistance transcriptome of various cancer cell types, no correlation was found between clinical samples and established cancer cell lines [25].”
BackgroundEhmsen, S., Pedersen, M. H., Wang, G., Terp, M. G., Arslanagic, A., Hood, B. L., Conrads, T. P., Leth-Larsen, R., & Ditzel, H. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.104 · Cited by 173
“The model of choice has often been long-established cancer cell lines; however, molecular profiling of the NCI-60 panel of well-established cancer cell lines compared to primary human cancer tissues revealed that cell lines cluster with cell lines instead of their tissue of origin (Gillet et al., 2011).”
Background3D scaffolds in breast cancer research
Rijal, G., & Li, W. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.016 · Cited by 169
“The analytical results on about 400 of the multidrug resistance (MDR)-related genes showed no correlation between the established cancer cell lines and clinical tumor samples representing six cancer types, regardless of 2D, 3D, or xenograft culturing conditions[235].”
BackgroundInfluentialRapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems
Nestor, C. E., Ottaviano, R., Reinhardt, D., Cruickshanks, H. A., Mjoseng, H. K., McPherson, R. C., Lentini, A., Thomson, J. P., Dunican, D. S., Pennings, S., et al. (2015) · Genome Biology · doi:10.1186/s13059-014-0576-y · Cited by 173
“Our findings reinforce a growing realization that cell line models of human diseases, particularly cancer, can be poor surrogates for many aspects of in vivo biology, as emphasized in a recent study of multi-drug resistance genes in ovarian cancer, in which no correlation in expression was found between primary ovaria…”
BackgroundComputational models for predicting drug responses in cancer research
Azuaje, F. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw065 · Cited by 59
DeepDSC: A Deep Learning Method to Predict Drug Sensitivity of Cancer Cell Lines
Li, M., Wang, Y., Zheng, R., Shi, X., Li, Y., Wu, F.-X., & Wang, J. (2021) · IEEE/ACM Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2019.2919581 · Cited by 160
“CULTURED Cancer cell lines with heterogeneous genomic backgrounds and gene expressions are fundamental materials to study the molecular basis of drug activity [1] and to discover novel anticancer drugs in cancer biology, despite their genomic differences from original tissue or tumor samples [2], [3].”
BackgroundHeralding a new paradigm in 3D tumor modeling
Fong, E. L. S., Harrington, D. A., Farach‐Carson, M. C., & Yu, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.052 · Cited by 164
Gottesman, M. M., & Pastan, I. H. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv222 · Cited by 153
An Organoid-Based Preclinical Model of Human Gastric Cancer
Steele, N. G., Chakrabarti, J. L., Wang, J., Biesiada, J., Holokai, L. L., Chang, J., Nowacki, L. M., Hawkins, J., Mahé, M. M., Sundaram, N., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.008 · Cited by 154
“However, several studies reveal a drift at the transcriptomic level, demonstrating that cancer cell lines carry more resemblance to each other rather than to the clinical samples from which they were originally derived.(9,10) Our study reports the use of three-dimensional organoids as a potential tool used for the pre…”
ResultRecurrent Oral Cancer: Current and Emerging Therapeutic Approaches
da Silva, S. D., Hier, M., Mlynarek, A., Kowalski, L. P., & Alaoui‐Jamali, M. A. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00149 · Cited by 138
Understanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 167
“This variability might also explain why contradictory results are sometimes obtained from in vitro experiments even under identical experimental conditions 21 .”
Tumor organoid models in precision medicine and investigating cancer-stromal interactions
Xu, R., Zhou, X., Wang, S., & Trinkle, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107668 · Cited by 134
Jensen, D., Dabelsteen, E., Specht, L., Fiehn, A. K., Therkildsen, M. H., Jønson, L., Vikesaa, J., Nielsen, F. C., & von Buchwald, C. (2015) · The Journal of Pathology · doi:10.1002/path.4550 · Cited by 132
“Large differences would be expected, because in vitro culture of primary cells has been shown to profoundly alter their transcriptome, and therefore their phenotype [34,35].”
BackgroundVougas, K. N., Sakellaropoulos, T., Kotsinas, A., Foukas, G.-R. P., Ntargaras, A., Koinis, F., Polyzos, A., Myrianthopoulos, V., Zhou, H., Narang, S., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107395 · Cited by 138
Investigational ABC transporter inhibitors
Falasca, M., & Linton, K. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679339 · Cited by 128
“A recent study raised concerns on the use of cell lines after quantitative RT-PCR was used to investigate their ABC transporter transcriptomes in comparison to primary tumours from six cancer types [91].”
MethodRambow, F., Job, B., Petit, V., Gesbert, F., Delmas, V., Seberg, H., Meurice, G., Otterloo, E. V., Dessen, P., Robert, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.037 · Cited by 129
“Melanoma tumors and derived cell lines clustered separately, as is the case for other cancer types (Gillet et al., 2011), whether we used global mRNA levels (17,322 unique genes) (Figure S1A), the 5,000 genes with the most variable expression (Figure S1B), or 244 multidrug resistance (MDR) genes…”
Pettersen, E. O., Ebbesen, P., Gieling, R. G., Williams, K. J., Dubois, L. J., Lambin, P., Ward, C., Meehan, J., Kunkler, I. H., Langdon, S. P., et al. (2014) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2014.966704 · Cited by 129
Kimple, R. J., Harari, P. M., Torres, A. D., Yang, R., Soriano, B. J., Yu, M., Armstrong, E. A., Blitzer, G. C., Smith, M. A., Lorenz, L. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2746 · Cited by 110
Liu, K., Newbury, P. A., Glicksberg, B. S., Zeng, B., Paithankar, S., Andrechek, E. R., & Chen, B. (2019) · Nature Communications · doi:10.1038/s41467-019-10148-6 · Cited by 130
Humanized Rodent Models for Cancer Research
Tian, H., Lyu, Y., Yang, Y., & Hu, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01696 · Cited by 116
“These shortcomings are most apparent when these cell lines are compared with their parental cancer strains from sick patients, implying that using these cell lines may compromise the value of any anticancer drug efficacy predictions in a clinical setting (27, 28).”
BackgroundBreast cancer liver metastasis: current and future treatment approaches
Rashid, N. S., Grible, J. M., Clevenger, C. V., & Harrell, J. C. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10080-4 · Cited by 117
The Merkel Cell Polyomavirus Minor Capsid Protein
Schowalter, R. M., & Buck, C. B. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003558 · Cited by 110
“Although it may seem counter-intuitive that MCC lines carrying integrated MCV genomes are resistant to MCV infection, it is important to note that progression to malignancy and adaptation to culture are typically associated with a large number of genetic, epigenetic, and phenotypic changes [60].”
BackgroundOverview of the Use of Murine Models in Leukemia and Lymphoma Research
Kohnken, R. A., Porcu, P., & Mishra, A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00022 · Cited by 122
“Limitation of cancer cell lines, include adaptation to in vitro culture for extended periods of time and the selective pressure therein, which is not reverted during xenografting (12, 13), and the relatively minimal genetic diversity available in cell lines as compared to the tumors from which they derive (14, 15).”
BackgroundBeyond 3D culture models of cancer
Tanner, K., & Gottesman, M. M. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3009367 · Cited by 109
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., Schneider, L., Muckenhuber, A., Hong, Y., Siegers, G., Nilsson, L. M., Wirth, M., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317856 · Cited by 106
Mao, S., He, J., Zhao, Y., Liu, T., Xie, F., Yang, H., Mao, Y., Pang, Y., & Sun, W. (2020) · Biofabrication · doi:10.1088/1758-5090/aba0c3 · Cited by 106
Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research
Cogels, M., Rouas, R., Ghanem, G., Martinive, P., Awada, A. H., Gestel, D. V., & Krayem, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.784947 · Cited by 115
“The latter methods are widely used in cancer research, yet although CDXs are less time-consuming, the in vitro culture step before engraftment may lead to a substantial loss of primary tumor features (7).”
MethodTorresi, J., Tran, B. M., Christiansen, D., Earnest-Silveira, L., Schwab, R., & Vincan, E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5916-6 · Cited by 102
Evolution of the Experimental Models of Cholangiocarcinoma
Massa, A., Varamo, C., Vita, F., Tavolari, S., Neia, C. P., Brandi, G., Rizzo, A., Cavalloni, G., & Aglietta, M. (2020) · Cancers · doi:10.3390/cancers12082308 · Cited by 96
Hydrogel-Based 3D Model of Patient-Derived Prostate Xenograft Tumors Suitable for Drug Screening
Fong, E., Martinez, M., Yang, J., Mikos, A., Navone, N., Harrington, D., & Farach-Carson, M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500085p · Cited by 91
Jeppesen, M., Hagel, G., Glenthøj, A. J., Vainer, B., Ibsen, P. H., Harling, H., Thastrup, M., Jørgensen, L. N., & Thastrup, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183074 · Cited by 97
Orthotopic and metastatic tumour models in preclinical cancer research
Stribbling, S. M., Beach, C., & Ryan, A. J. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108631 · Cited by 102
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review
Lloyd, K. L., Cree, I. A., & Savage, R. S. (2015) · BMC Cancer · doi:10.1186/s12885-015-1101-8 · Cited by 87
“[16], that gene signatures obtained from cancer cell lines are not always relevant to in vivo studies, and that cell lines are inaccurate models of chemosensitivity [17].”
BackgroundOrganoids: An intermediate modeling platform in precision oncology
Jin, M., Han, R.-R., Qiu, G., Ju, X.-C., Lou, G., & Jin, W. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.021 · Cited by 96
Proposed Molecular and miRNA Classification of Gastric Cancer
Alessandrini, L., Manchi, M., Re, V. D., Dolcetti, R., & Canzonieri, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061683 · Cited by 91
Meena, A. S., Sharma, A., Kumari, R., V, Mohammad, N., Singh, S. V., & Bhat, M. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061524 · Cited by 85
“Use of available cell lines can address only one aspect of human drug resistance and hence disparities and misinterpretations are inevitable when a comparison is drawn between in vitro and in vivo observations [30].”
BackgroundOrganoids as Models for Neoplastic Transformation
Neal, J. T., & Kuo, C. J. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044249 · Cited by 87
Predicting and characterizing a cancer dependency map of tumors with deep learning
Chiu, Y.-C., Zheng, S., Wang, L.-J., Iskra, B. S., Rao, M. K., Houghton, P. J., Huang, Y., & Chen, Y. (2021) · Science Advances · doi:10.1126/sciadv.abh1275 · Cited by 84
“Furthermore, a model trained using merely CCL data may not fully capture tumor-specific contexts such as tumor heterogeneity and its microenvironment (19, 20).”
MethodConditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
Palechor-Ceron, N., Krawczyk, E., Dakic, A., Simić, V., Yuan, H., Blancato, J. K., Wang, W., Hubbard, F. A., Zheng, Y., Dan, H., et al. (2019) · Cells · doi:10.3390/cells8111327 · Cited by 84
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines
Hofving, T., Arvidsson, Y., Almobarak, B., Inge, L., Pfragner, R., Persson, M., Stenman, G., Kristiansson, E., Johanson, V., & Nilsson, O. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0445 · Cited by 86
“2006, Gillet et al .”
Won, W.-J., Deshane, J. S., Leavenworth, J. W., Oliva, C. R., & Griguer, C. E. (2019) · Cell Stress · doi:10.15698/cst2019.02.176 · Cited by 87
“For these reasons it is difficult to directly translate traditional glioblastoma xenograft mouse models to human glioblastoma cases and test drug candidates with these mouse models for pre-clinical study [133, 134].”
BackgroundNanni, P., Landuzzi, L., Manara, M. C., Righi, A., Nicoletti, G., Cristalli, C., Pasello, M., Parra, A., Carrabotta, M., Ferracin, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48634-y · Cited by 82
Sinha, R., Winer, A., Chevinsky, M. S., Jakubowski, C. D., Chen, Y., Dong, Y., Tickoo, S. K., Reuter, V. E., Russo, P., Coleman, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15165 · Cited by 86
Organoid Models of Glioblastoma and Their Role in Drug Discovery
Rybin, M. J., Ivan, M. E., Ayad, N. G., & Zeier, Z. R. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.605255 · Cited by 88
“However, use of these established lines is increasingly controversial due to important differences when compared to in situ GBM (Gillet et al., 2011; Allen et al., 2016).”
BackgroundNecroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II
Xiong, K., Qian, C., Yuan, Y., Wei, L., Liao, X., He, L., Rees, T. W., Chen, Y., Wan, J., Ji, L., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006089 · Cited by 82
Deep learning of pharmacogenomics resources: moving towards precision oncology
Chiu, Y., Chen, H.-I. H., Gorthi, A., Mostavi, M., Zheng, S., Huang, Y., & Chen, Y. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz144 · Cited by 93
“…of CCLs resembles genomic or pathway alterations found in primary tumors [15,61, 133–135], it has long been questioned whether in vitro models fully recapitulate primary tumors’ heterogeneity and microenvironment for clinically relevant drug response prediction and drug discovery [136–138].”
BackgroundEntry Tropism of BK and Merkel Cell Polyomaviruses in Cell Culture
Schowalter, R. M., Reinhold, W. C., & Buck, C. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042181 · Cited by 83
“While it is tempting to speculate that infectivity of a tumor cell line from a particular organ is indicative of potential infection of that organ in vivo, an important caveat to this approach is highlighted by a recent study suggesting that various tumor cell lines grown in culture are in many ways more similar to ot…”
BackgroundMetabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond
Teoh, S. T., & Lunt, S. Y. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1406 · Cited by 85
Liu, R., Garcia, E., Glubrecht, D. D., Poon, H. Y., Mackey, J. R., & Godbout, R. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0380-7 · Cited by 79
“glioma cell lines compared to tumor tissue [39–41].”
ResultLi, C., Huang, J., Yu, Y., Wan, Z., Chiu, M. C., Liu, X., Zhang, S., Cai, J., Chu, H., Li, G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300376120 · Cited by 82
Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis
Murphy, B., Yin, H., Maris, J. M., Kolb, E. A., Gorlick, R., Reynolds, C. P., Kang, M. H., Keir, S. T., Kurmasheva, R. T., Dvorchik, I., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0122 · Cited by 69
Yu, J., Qin, B., Moyer, A. M., Sinnwell, J. P., Thompson, K. J., Copland, J. A., Marlow, L. A., Miller, J. L., Yin, P., Gao, B., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0920-8 · Cited by 77
“Conventional xenograft models generated with cancer cell lines have limitations, such as inability to capture tumor heterogeneity [1, 11, 12] or recapitulate the spectrum of human breast cancer due to distinct differences in mice strains, cell origins and the tumor microenvironment, all of which limit their predictive…”
Backgroundde Ronde, J. J., Lips, E. H., Mulder, L., Vincent, A. D., Wesseling, J., Nieuwland, M., Kerkhoven, R. M., Peeters, M.-J. T. F. D. V., Sonke, G. S., Rodenhuis, S., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2340-x · Cited by 68
Immuno-oncology trends: preclinical models, biomarkers, and clinical development
Franklin, M. R., Platero, S. J., Saini, K. S., Curigliano, G., & Anderson, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003231 · Cited by 74
Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research
Overgaard, N. H., Fan, T. M., Schachtschneider, K. M., Principe, D. R., Schook, L. B., & Jungersen, G. (2018) · ILAR Journal · doi:10.1093/ilar/ily014 · Cited by 72
Targeting of Rac GTPases blocks the spread of intact human breast cancer
Katz, E., Sims, A. H., Sproul, D., Caldwell, H., Dixon, J. M., Meehan, R. R., & Harrison, D. J. (2012) · Oncotarget · doi:10.18632/oncotarget.520 · Cited by 60
“Furthermore, there are serious doubts regarding the relevance of drug testing in established cancer cell lines and transfer of results to the clinic [3].”
BackgroundConditional reprogramming: next generation cell culture
Wu, X., Wang, S., Li, M., Li, J., Shen, J., Zhao, Y., Pang, J., Wen, Q., Chen, M., Wei, B., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.011 · Cited by 68
Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways
Esparza‐López, J., Alvarado-Muñoz, J. F., Escobar-Arriaga, E., Ulloa‐Aguirre, A., & Ibarra-Sánchez, M. D. J. (2019) · BMC Cancer · doi:10.1186/s12885-019-5945-1 · Cited by 64
Durinikova, E., Buzo, K., & Arena, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01981-z · Cited by 67
Ahmad, G., Sadda, R. R. E., Botchkina, G. I., Ojima, I., Egan, J., & Amiji, M. M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.004 · Cited by 63
Discovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 63
Tan, P., Wang, M., Zhong, A., Wang, Y., Du, J., Wang, J., Qi, L., Bi, Z., Zhang, P., Lin, T., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01999-9 · Cited by 65
“It has been shown that cancer cell lines have alterations in biologic properties, including genetic expression alteration, biological behaviors change, and heterogeneity loss [5].”
BackgroundMartinez‐Outschoorn, U., Balliet, R. M., Zhao, L., Whitaker‐Menezes, D., Howell, A., Sotgia, F., & Lisanti, M. P. (2012) · Cell Cycle · doi:10.4161/cc.22226 · Cited by 64
Jiang, P., Lee, W., Li, X., Johnson, C., Liu, J. S., Brown, M. A., Aster, J. C., & Liu, X. S. (2018) · Cell Systems · doi:10.1016/j.cels.2018.01.009 · Cited by 62
“In addition, the clinical relevance of cell line models has been continuously questioned (Gillet et al., 2011, 2013).”
Loessner, D., Holzapfel, B. M., & Clements, J. A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.001 · Cited by 61
Natural Products That Target Cancer Stem Cells.
Moselhy, J., Srinivasan, S., Ankem, M. K., & Damodaran, C. (2015) · PubMed · Cited by 57
Choudhuri, S., Patton, G. W., Chanderbhan, R. F., Mattia, A., & Klaassen, C. D. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx186 · Cited by 63
“This was demonstrated by Gillet et al. (2011) who studied the known multidrug resistance (MDR) transcriptome of 6 cancer types in established cancer cell lines (grown in monolayer, 3D scaffold, or in xenograft) and clinical samples.”
BackgroundWeiswald, L., Richon, S., Massonnet, G., Jm, G., Vacher, S., Laurendeau, I., Cottu, P. H., Marangoni, E., Némati, F., Validire, P., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.132 · Cited by 57
“Recent attention has focused on the need for better models that preserve the integrity of cancer stem cell (CSC) populations, as well as 3D microenvironmental interactions (Schmeichel and Bissell, 2003; Vaira et al, 2010; Gillet et al, 2011).”
BackgroundPathophysiologically relevant in vitro tumor models for drug screening
Das, V., Bruzzese, F., Konečný, P., Iannelli, F., Budillon, A., & Hajdúch, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.04.004 · Cited by 61
Patient-derived xenografts as preclinical neuroblastoma models
Braekeveldt, N., & Bexell, D. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2687-8 · Cited by 54
“While conventional cancer cell lines cultured in serumcontaining medium as 2D monolayers have their advantages, these cells might not accurately resemble the disease (Gillet et al. 2011; Lee et al. 2006) and only poorly predict clinical outcome (Johnson et al. 2001).”
BackgroundFeature selection strategies for drug sensitivity prediction
Koras, K., Juraeva, D., Kreis, J., Mazur, J., Staub, E., & Szczurek, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-65927-9 · Cited by 57
Chang, Y.-W., Zhao, Y., Gu, W., Cao, Y., Wang, S., Pang, J., & Shi, Y.-Y. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430289 · Cited by 52
Rottenberg, S., Vollebergh, M. A., de Hoon, B., de Ronde, J., Schouten, P. C., Kersbergen, A. J., Zander, S. A. L., Pajic, M., Jaspers, J. E., Jonkers, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4201 · Cited by 52
“Moreover, cell line–based approaches to identify biomarkers suffer from the complication that the multidrug resistance transcriptome has been substantially altered during the long-term culture of these cell lines in vitro (16).”
BackgroundPal, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-805274-7.00004-x · Cited by 53
Cancer mouse models: Past, present and future
Khaled, W. T., & Liu, P. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.04.003 · Cited by 59
Algorithms for Drug Sensitivity Prediction
Niz, C. D., Rahman, R., Zhao, X., & Pal, R. (2016) · Algorithms · doi:10.3390/a9040077 · Cited by 59
“However, the laboratory environment along with the absence of other regular cell types within the cell line restricts the ability of a cell line itself to mimic in vivo cancer growth, as well as the efficacy of anti-cancer drugs [4].”
BackgroundKaliszczak, M. A., van Hechanova, E., Li, Y., Al-Sadah, H. A., Parzych, K., Auner, H. W., & Aboagye, E. O. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0232-5 · Cited by 51
Metadata
- Authors
- Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., Padmanabhan, R., Davidson, B., Ganapathi, R., Sood, A. K., Rueda, B. R., Ambudkar, S. V., & Gottesman, M. M.
- Affiliations
- National Cancer Institute (UA)
- National Institutes of Health (US)
- Biophase Systems, Fremont, CA 94539;
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-11-08
- Volume
- 108
- Issue
- 46
- Pages
- 18708-18713
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3219108
- OpenAlex
- W2018044006
- Cited by
- 477
- References
- 46
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 43 · 2022: 28 · 2021: 34 · 2020: 41 · 2019: 45 · 2018: 33 · 2017: 46 · 2016: 40 · 2015: 40 · 2014: 20 · 2013: 29 · 2012: 16
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Namur (submittedVersion)
- Funders
- Georgetown University
- Karolinska Institutet
- National Institutes of Health
- Lombardi Comprehensive Cancer Center, Georgetown University
- National Cancer Institute (NCI-60)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- cancer cell lines, multidrug resistance, drug resistance mechanisms, xenografts, 3D cell culture, gene expression profiles, in vitro tumor model, tumor microenvironment
- MeSH terms
- Antineoplastic Agents, Cell Survival, Drug Screening Assays, Antitumor, Female, Humans, Ovarian Neoplasms, Ovary, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Cell Line, Tumor, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.